ArticleJournal of applied clinical medical physics2026
Task-based image quality and dosimetric validation of HyperSight CBCT for adaptive radiotherapy.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCone-beam computed tomography (CBCT) is increasingly used in adaptive radiotherapy (ART), yet the dosimetric accuracy and image quality of advanced CBCT imaging platforms-such as Halcyon HyperSight 4.0 (HH), which combines an upgraded detector panel with advanced iterative reconstruction, scatter-correction, and metal-artifact-reduction algorithms-remain insufficiently characterized clinically. PURPOSE: To evaluate HH CBCT reconstruction algorithms for ART by assessing image quality, dose accuracy, and in vivo verification using optically stimulated luminescence dosimeters (OSLDs).
methodsTask-based image quality was evaluated with ImQuest per AAPM TG-233 using a Gammex 464 ACR phantom on three systems: Canon Aquilion Large Bore CT (LB, reference), TrueBeam (TB), and HH. Seven algorithms were compared (LB, TB-FDK, TB-iCBCT, HH-FDK, HH-iCBCT, HH-Acuros, HH-MAR), with d' (the detectability index, a task-based image-quality metric per AAPM TG-233) derived for four insert materials (polyethylene, acrylic, bone, air). A volumetric modulated arc therapy (VMAT) plan was independently re-optimized (using identical optimization objectives/constraints as the LB reference plan) on HH-iCBCT, HH-Acuros, and HH-MAR images and verified by portal dosimetry (1%/1 mm gamma), delivered to an Alderson RANDO phantom with dose measured at 15 points (2 clinical target volume [CTV], 7 organ-at-risk [OAR], and 6 lung points) using BeO OSLDs and compared to LB (± 5% criterion). Mean d' per algorithm was compared to LB via one-sample t-tests (p < 0.05).
resultsHH-iCBCT (d' = 4.70, p = 0.016), HH-Acuros (d' = 4.61, p = 0.005), and HH-MAR (d' = 4.71, p = 0.024, numerically highest) showed significant detectability improvement over LB (d' = 4.42), with HH-iCBCT most consistent across materials. Mean absolute OSLD dose errors were 1.71%, 2.09%, and 2.90%; all 15 points met the ± 5% criterion except Lt_lung2 in HH-MAR (-5.32%).
conclusionHH-iCBCT demonstrated clinically acceptable image quality and dose accuracy for CBCT-based ART, supported by in vivo BeO OSLD verification in an anthropomorphic phantom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.